Search results

Every person’s experience living with neuroendocrine tumors (NETs) is unique and for Melanie, coming to terms with a diagnosis of lung NETs is an ongoing journey, building knowledge and understanding of how to live with this complex and often unknown for...

L’expérience de chaque personne atteinte de tumeurs neuroendocrines (TNE) est unique. Pour Mélanie, accepter le diagnostic d’une TNE pulmonaire s’inscrit dans un processus continu, fait de recherches, de découvertes et d’apprentissage, pour mieu...

...

...

PARIS, FRANCE, 20 December 2021 - 6:00 PM CET - Ipsen has learned that Cipla Limited and its subsidiary Cipla USA, Inc. has received final approval of a lanreotide product from the U.S. Food and Drug Administration; the FDA approval was based on a New Drug...

PARIS, FRANCE, 20 Décembre 2021 – 18 :00 CET – Ipsen a appris que Cipla Limited et sa filiale Cipla USA, Inc. ont reçu l’approbation finale de la Food and Drug Administration américaine pour un produit lanréotide ; l’approbation de la...

When Ioana Parsons, General Manager of the UK & Ireland, thinks about continuous learning, she sees one part of a larger puzzle. “Business performance reflects overall organizational health,” she says. “Plenty of data shows that ‘healthy’ org...

As anyone living with Primary Biliary Cholangitis (PBC) – a rare and progressive autoimmune liver disease1 – knows, the disease can have a significant impact on a person’s day to day life and relationships.2 ...

PARIS, FRANCE, 8 March 2021 – Ipsen has learned that Amdipharm Ltd, which is believed to be a subsidiary of Advanz Pharma, has received a positive outcome by the Reference Member State, Denmark, and closure of the Decentralised Procedure, for a generic f...

Paris (France), le 8 mars 2021 – Ipsen a appris qu’Amdipharm Ltd, qui serait une filiale d’Advanz Pharma, a reçu une réponse favorable par le Danemark, État membre de référence pour la procédure européenne décentralisée, pour une f...